24. QUALITY OF LIFE AMONG LUNG CANCER PATIENTS AFTER RADIATION THERAPY AT THE NATIONAL LUNG HOSPITAL IN 2020

Tran Thi Ly1, Le Thi Hang2, Hoang Thu Thuy3, Ha Thi Men1
1 National Lung Hospital
2 University of Medicine and Pharmacy, Vietnam National University
3 DECA CARE Center of Cancer

Main Article Content

Abstract

Background: Lung cancer is a common malignancy, the leading cause of cancer death worldwide. Caring and treating for lung cancer patients is a process that requires the patient and their family to have perseverance, faith and great efforts both physically and mentally.


Objective: Description the quality of life among lung cancer patients after radiation therapy at the National Lung Hospital in 2020. Methods: Cross-sectional study. The study collected information from patients with lung cancer after radiation therapy in the National Lung Hospital through standardized EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires in Vietnam. The patient’s CLCS was evaluated according to 5 functionals and clinical symptoms. Data were entered by Epidata 3.1 and analyzed by SPSS 18.0.


Results and conclusion: The finding showed that, QoL of patients was average (55.1 points), physical function (69.5 points), cognitive function (65.6 points), operational function (62.5 points), emotional function (56.3 points) and social functioning (51.4 points). Common symptoms of patients after radiation therapy include: sleep disturbance (39.8 points), loss of appetite (35.2 points), pain (33.2 points), fatigue (29.4 points), shortness of breath (25.7 points), nausea, constipation (18.6 points) and diarrhea (9.2 points).

Article Details

References

[1] Bray F, Ferlay J, Soerjomataram I et al., Global
cancer statistics 2018: GLOBOCAN estimates
of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin.
2018;68(6):394-424.
[2] Nguyễn Khắc Kiểm, Nghiên cứu nạo vét hạch
theo bản đồ trong phẫu thuật điều trị ung thư phổi
không tế bào nhỏ giai đoạn I-II-IIIA, Luận án
Tiến sĩ y học, Trường Đại học Y Hà Nội; 2016.
[3] Di Maio M, Leighl NB, Gallo C et al., Quality
of life analysis of TORCH, a randomized trial
testing first-line erlotinib followed by secondline
cisplatin/gemcitabine chemotherapy in
advanced non-small-cell lung cancer. J Thorac
Oncol; 2012;7(12):1830-1844.
[4] Đặng Văn Khoa, Nguyễn Việt Hà, Đánh giá hiệu
quả phác đồ Paclitaxel-Cisplatin trong điều trị
ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV.
Tạp chí Y học thực hành; 2013;6(873):28-31.
[5] Nguyễn Thị Thanh Mai, Phân tích tình hình sử
dụng thuốc và đánh giá chất lượng cuộc sống
bệnh nhân ung thư phổi không tế bào nhỏ điều
trị tại Trung tâm Y học hạt nhân và ung bướu
Bệnh viện Bạch Mai, Luận văn Thạc sĩ Dược
học, Trường Đại học Dược Hà Nội; 2015.
[6] Wu YL, Chu DT, Han B et al., Phase III,
randomized, open-label, first-line study in Asia
of gefitinib versus carboplatin/paclitaxel in
clinically selected patients with advanced nonsmall-
cell lung cancer: evaluation of patients
recruited from mainland China. Asia-Pacific
journal of clinical oncology; 2012;8(3):232-243.
[7] Yucel B, Akkaş EA, Okur Y et al., The impact
of radiotherapy on quality of life for cancer
patients: a longitudinal study. Supportive care
in cancer : official journal of the Multinational
Association of Supportive Care in Cancer;
2014;22(9):2479-2487.
[8] Braun DP, Gupta D, Staren ED, Quality of life
assessment as a predictor of survival in non-small
cell lung cancer. BMC Cancer; 2011;11(1):353.